Phase III clinical trial - Appareil pulmonaire

MARIPOSA - 73841937NSC3003
Appareil pulmonaire
Ouvert depuis le: 09.17.2021
Site: Paris
Public cible
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy;Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with;EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer;MARIPOSA
Description de l'essai

This randomized, multicenter, Phase 3 study will compare the efficacy and safety of combining;amivantamab and lazertinib (Arm A) versus single-agent osimertinib (Arm B) as first-line treatment in;participants with EGFR-mutated locally advanced or metastatic NSCLC not amenable to curative therapy.;Combining amivantamab and lazertinib may lead to improved treatment outcomes through synergistic;anti-EGFR activity, prevention of EGFR- or MET-based resistance to a third-generation EGFR TKI, and;potential recruitment of Fc-bearing immune cells in the anti-tumor response. The contribution of;amivantamab to the activity of the combination will be assessed by comparing the efficacy observed in the;amivantamab and lazertinib combination arm (Arm A) with that in a lazertinib monotherapy arm (Arm C).